Tempus AI Inc / TEM

Equity | Generated Sep 10, 2026 11:32 PM EDT

Current price	Daily move	Bid / Ask	Previous close
$58.82	**-2.46 -4.01%**	**$58.26/$59.00**	**$61.28**

Market	**NYSE**
Industry	**Life Sciences Tools & Services**
Market data as of	**Sep 10, 2026 11:32 PM EDT**

JW Intelligence Report

Complete | 3 of 3 sections | Sep 10, 2026 6:51 PM EDT

JW Rank	Rank label	Confidence	IV percentile
54.8 / 100	**Balanced**	**high**	**50 / 100**

Model reference	Upside scenario	Risk reference	Wheel strategy fit
$56.50	**$64.00**	**$52.00**	**58 / 100**

Options stance	**mixed**
Tail-risk safety	**56 / 100**
JW Rank data coverage / as of	**97.1% | Sep 10, 2026 6:51 PM EDT**

Key insight

TEM Option Market Shows Uncertainty Amidst Mixed Signals

Market read

The TEM option market reflects uncertainty surrounding the company's future. While recent news includes FDA clearances and analyst upgrades, concerns about the Personalis acquisition and mixed technical signals contribute to a cautious outlook. The term structure exhibits backwardation with higher implied volatility for near-term expirations.

Strategy context

Option pricing reflects a balance between bullish sentiment driven by recent FDA approvals and growth prospects, and bearish concerns regarding the dilutive impact of the Personalis acquisition and mixed technical signals.

JW AI conclusions

Short- and medium-term model interpretation

AI context bias	**Bearish**
AI analysis updated	**Sep 10, 2026 2:26 PM EDT**

Short-term scenario

Cautious wait-and-see or small dip-buy if support holds; high uncertainty from today's decline, mixed technicals, and upcoming conference. Not a high-conviction 1-3 week trade.

Three-month outlook

Moderately constructive on 25%+ revenue growth, new FDA-cleared products, data/pharma partnerships, and potential Personalis MRD synergy, with path toward Adj. EBITDA positivity. However, very high uncertainty: acquisition dilution/execution risk (close late 2026/early 2027), still-negative GAAP earnings and cash burn, rich 7.6x P/S valuation, elevated short interest, and sector/AI sentiment swings. Could trade $50-75 range depending on Q3 results, deal progress, and broader market. Volatility remains elevated.

Market sentiment

Mixed/cautious with no strong consensus. Some traders note gapping lower to support and watch for reversal at 8-week MA or 21 EMA; others advise 'don't buy'. Longer-term posts highlight AI/healthcare potential, founder stake, pharma partnerships (AstraZeneca, Merck etc.), but recent comments flag dilution from Personalis deal, cash burn, and valuation. Promotional/spam posts common. Overall uncertain and not aggressively bullish near-term.

Supporting evidence

Implied volatility is elevated at 67.88%, suggesting market participants anticipate significant price swings. | The skew is call-demand elevated, indicating a preference for bullish bets on TEM's upside potential. | Short-term technical indicators are mixed, with the stock trading below short-term moving averages but above longer-term support levels. | Recent news includes both positive developments (FDA clearances, analyst upgrades) and concerns (acquisition dilution, cash burn) | The market is awaiting key events like the CEO fireside chat and the Personalis acquisition close for further direction.

Risk watch

The Personalis acquisition could face delays or integration challenges, impacting stock performance.

Enhanced price structure

45 trading days with volume, model levels and current technical reference bands

45 complete trading-session observations

JW Rank factors

Score, source coverage and interpretation for each decision factor

JW RANK FACTOR PROFILE	COVERAGE	Score (0–50–100)
Liquidity	100.0%	73.5
Strategy Fit	100.0%	58.2
Technical Trend	100.0%	66.7
Market Tail Risk	100.0%	56.3
Fundamental Quality	71.4%	22.3
Volatility Pressure	100.0%	31.9

Decision summary

Primary model reads before the detailed indicator appendix

Momentum	Institutional flow	Structure	Volatility
bullish_recovery	**Below MVWAP**	**Above 200D trend**	**high**

Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	**BULLISH RECOVERY | neutral | MACD decelerating**
Trend signal	**BULLISH RECOVERY**
RSI signal	**neutral**
RSI (7 / 14 / 21)	**36.09 / 47.86 / 50.60**
RSI velocity	**-3.26**
MACD line / signal / histogram	**2.25 / - / 3.18**
MACD acceleration	**-0.38**
Stochastic K / D	**22.17 / 41.63**

Institutional footprints

Volume-weighted cost, price location and flow

Current read	**Below institutional MVWAP | Accumulation bias**
Institutional flow	**0.18**
20-day MVWAP	**$64.10**
Price vs 20-day MVWAP	**-8.24%**
Daily reference VWAP	**$59.29**
Price vs daily reference	**-0.79%**
Volume	**3.63M**

Structural context

Long-term trend and volatility boundaries

Current read	**Above 200-day trend | Positive macro velocity**
Macro velocity	**0.32**
20-day / 200-day SMA	**$62.35 / $56.32**
Bollinger range	**$49.58 - $75.12**
Bollinger position	**0.359**

Options and volatility intelligence

Structure, premium conditions and principal risks

IV rank	IV percentile	VVIX	SKEW
46 / 100	31 / 100	101.82	149.25

Market regime	**Calm**
Tail-risk regime	**NORMAL TAIL RISK**
Term structure	**backwardation**
Term slope	**-17.40 pts**
Skew read	**CALL DEMAND ELEVATED**
Liquidity / quote coverage	**92.9%**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Sep 10, 2026 2:59 PM EDT**
Options data quality	**Coverage 88.9%**

Option term structure

ATM implied-volatility curve by days to expiration

ATM IV CURVE



Downward-sloping ATM volatility term structure

EXPIRATION	DTE	ATM IV	STATE
2026-09-11	1	88.5%	-
2026-09-18	8	72.6%	-
2026-09-25	15	71.1%	-

Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit

Bull Put Spread reference

Short $56.00 | Long $55.00 | Width $1.00 | Net credit $0.08



Max profit $8.00 | Max loss -$92.00 | Break-even $55.92 | Per contract at expiry

Bear Call Spread reference

Short $61.00 | Long $62.00 | Width $1.00 | Net credit $0.17



Max profit $17.00 | Max loss -$83.00 | Break-even $61.17 | Per contract at expiry

Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	**2026-11-03**
Earnings IV-crush risk	**NOT MEASURED**
VIX	**17.82**
VVIX	**101.82**
SKEW index	**149.25**
Observation confidence	**high**
Option quote quality	**reliable**
Contracts observed	**127**

Event and tail-risk context (continued)

Known event windows and broad volatility conditions

FIELD	VALUE
Contracts with quotes	**118**

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

The TEM option market reflects uncertainty surrounding the company's future. While recent news includes FDA clearances and analyst upgrades, concerns about the Personalis acquisition and mixed technical signals contribute to a cautious outlook. The term structure exhibits backwardation with higher implied volatility for near-term expirations.

Options context

TEM Option Market Shows Uncertainty Amidst Mixed Signals

Wheel context

Option pricing reflects a balance between bullish sentiment driven by recent FDA approvals and growth prospects, and bearish concerns regarding the dilutive impact of the Personalis acquisition and mixed technical signals.

Observed evidence

Implied volatility is elevated at 67.88%, suggesting market participants anticipate significant price swings. | The skew is call-demand elevated, indicating a preference for bullish bets on TEM's upside potential. | Short-term technical indicators are mixed, with the stock trading below short-term moving averages but above longer-term support levels. | Recent news includes both positive developments (FDA clearances, analyst upgrades) and concerns (acquisition dilution, cash burn) | The market is awaiting key events like the CEO fireside chat and the Personalis acquisition close for further direction.

Principal risks to monitor

The Personalis acquisition could face delays or integration challenges, impacting stock performance.

Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization **$10.60B**	ROE **-54.7%**
Revenue growth **58.3%**	EPS growth **-**
Operating margin **-21.4%**	Net profit margin **-17.8%**
Gross margin **-**	Free cash flow CAGR **-**
Debt / equity **2.52**	Dividend yield **-**
Beta **2.34**	52-week range **$40.77 - $104.32**

Company or fund profile

Issuer identity and classification

Name **Tempus AI Inc**	Market **NYSE**
Industry **Life Sciences Tools & Services**	Country **US**
Currency **USD**	IPO date **2025-05-30**
Shares outstanding **180.24M**	52-week return **-24.4%**
Book value per share **$2.47**	Revenue per share **$7.85**

Website	**investors.tempus.com**

Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	**$4.40**
ATR as % of price	**7.5%**
Volatility environment	**high**
Current IV	**71.8%**
IV rank	**55 / 100**
IV percentile	**50 / 100**
Technical Snapshot IV source	**Private fundamentals snapshot**
Technical Snapshot IV observed at	**Sep 10, 2026 7:32 PM EDT**

Technical health and risk radar

Derived indicator health and event context

Overall health	**66 / 100**
Trend health	**78 / 100**
Momentum health	**87 / 100**
Volatility health	**0 / 100**
Structure health	**86 / 100**
Earnings risk / date	**low | 2026-11-03**
Macro risk	**unknown**
Volatility risk	**high**
Structure risk	**low**

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	**$62.35 / $55.93 / $56.32**
EMA (9 / 21)	**$62.53 / $61.09**
Bollinger upper / middle / lower	**$75.12 / $62.35 / $49.58**

Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
Bollinger %B	**0.359**
True high / low	**$61.28 / $58.02**
5-day true high / low	**$66.30 / $58.02**

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	0.316	**-**
SMA50	0.080	**-**
MVWAP20	0.179	**-**
MACD	-0.384	**-**
RSI	-3.257	**-**
Volume	202763.330	**-**
ATR	-0.092	**-**
T1	-	**2.81 / 64.09 / 64.91 / 60.93**
T2	-	**3.23 / 63.98 / 65.79 / 63.21**
T3	-	**3.40 / 63.57 / 66.30 / 63.11**

Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	**$59.21**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Sep 10, 2026 2:59 PM EDT**
Options data coverage	**88.9%**
SKEW regime	**HIGH TAIL RISK SKEW**
VVIX regime	**VVIX RISING**
Front expiration / DTE	**2026-09-11 | 1 DTE**
Front at-the-money IV	**88.5%**
25-delta skew	**-9.36**
Put / Call 25-delta	**$56.00 / $61.00 Delta 0.281**
Median option bid/ask spread	**21.3%**
Bid/ask spread	**-**
Contracts observed / quoted	**127 / 118**

Price context

Last Price: 59.21 | Bid: 59.16 | Ask: 59.22 | Previous Close: 61.28 | Change: -2.07 | Daily change: -3.38% | Update Time: 2026-09-10T14:59:49.642303-04:00 | Latest History Date: 2026-09-10 | Latest History Price: 59.21

Historical context

Trading-day sample: 60 sessions | First Date: 2026-06-16 | Latest Date: 2026-09-10 | Latest Price: 59.21 | Max Drawdown 60d Percent: -32.55%

Fundamental context

Current Iv Percent: 67.88% | Iv Rank: 46.31 | Iv Percentile: 30.68 | Next Earnings Date: 2026-11-03 | Ex Dividend Date: N/A

Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	**jasonwheel.com**
Terms of Use	**jasonwheel.com / Terms**
Privacy Policy	**jasonwheel.com / Privacy**
Options Disclosure Document	**theocc.com / Options Disclosure Document**